Search Medical Condition
Please enter condition
Please choose location
 

Middlesex, United Kingdom Clinical Trials

A listing of Middlesex, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (1049) clinical trials

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients

Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral ...

Phase

0.0 miles

Learn More »

Combination Chemotherapy With or Without Filgrastim Before Surgery High-Dose Chemotherapy and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

OBJECTIVES: - Compare the efficacy of myeloablative therapy with busulfan and melphalan vs carboplatin, etoposide, and melphalan, in terms of 3- and 5-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS), in patients with high-risk neuroblastoma. - Compare the 3-year EFS in these patients treated with isotretinoin with ...

Phase

0.1 miles

Learn More »

Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms Hands Legs or Feet Treated on Clinial Trial CRUK-VORTEX

OBJECTIVES: - Determine early in the course of treatment which patients treated on clinical trial CRUK-VORTEX have an increased likelihood of distant metastases so as to highlight individuals who might benefit from early adjuvant systemic therapy. OUTLINE: This is a multicenter study. Tumour and normal tissue samples will be taken ...

Phase N/A

0.1 miles

Learn More »

Pharmacokinetics of Dactinomycin in Young Patients With Cancer

OBJECTIVES: - Determine the pharmacokinetics (PKs) of dactinomycin in pediatric patients with cancer. - Determine the degree of interpatient variation in the PKs of this drug. - Determine the influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs in these patients. - Correlate drug PKs ...

Phase N/A

0.1 miles

Learn More »

Ifosfamide and Doxorubicin Radiation Therapy and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

OBJECTIVES: Primary - Determine survival rates (event-free survival and overall survival [OS]) and the pattern of treatment failure in patients with synovial sarcoma or adult-type soft tissue sarcoma treated with ifosfamide and doxorubicin hydrochloride, radiotherapy, and/or surgery. - Determine the role of ifosfamide and doxorubicin hydrochloride in improving the response ...

Phase

0.1 miles

Learn More »

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

OBJECTIVES: - Improve the outcome in pediatric patients with low-risk rhabdomyosarcoma (RMS) treated with vincristine and dactinomycin alone. - Evaluate whether the outcome for older patients with standard-risk RMS with favorable features may be improved/maintained by administering a treatment with limited intensity. - Evaluate whether chemotherapy intensity for patients with ...

Phase

0.1 miles

Learn More »

Intermittent Versus Continuous Feeding in ICU Patients

This is a Phase II pilot single-blinded randomized controlled trial to be conducted in two adult intensive care units. Technically, the patient will be blinded (by virtue of illness), and in any case knowledge of the feeding intervention they are receiving would not influence outcome. Scans will be taken by ...

Phase

0.1 miles

Learn More »

Functional Genomic Influences on Disease Progression and Outcome in Sepsis

The investigators plan to recruit 2,000 cases of community acquired pneumonia (CAP) and 2,000 cases of faecal peritonitis (FP) from 30 UK ICUs and HDUs (members of the UK Critical Care Genomics group UKCCG). The large number of patients is required to satisfy the power calculations based upon the predicted ...

Phase N/A

0.1 miles

Learn More »

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

To assess if targeting activating EGFR and HER2 mutations in Non-Small Cell Lung Cancer (NSCLC) is more effective when these mutations are truncal dominant mutations (50%), as opposed to non-dominant (5 to <50%) or low frequency mutations (<5%). This trial will only be available to patients registered to the TRACERx ...

Phase

0.15 miles

Learn More »

PankoMab-GEX Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

The study is to evaluate the efficacy of PankoMab-GEX vs Placebo in maintaining response after 2nd to 4th line of chemotherapy in patients with epithelial ovarian or fallopian tube or primary peritoneal cancer. Patients must have responded to platinum based chemotherapy in a previous line, while the response to the ...

Phase

0.15 miles

Learn More »